Continuing Education
New Advances in JAK Inhibitors and non-JAK Inhibitors in Myelofibrosis: Updates from ASH 2023
Earn CME, CE |
Newsletter
Updates on Combination Therapies and Future Directions in Myelofibrosis
Haris Ali, MD and Andrew Kuykendall, MD
Dr. Ali and Dr. Kuykendall share their perspectives on combination therapies that will have an impact on future clinical practice in MF.
Read More |
Newsletter
Updates on JAK inhibitors in Myelofibrosis Newsletter
Stephen T. Oh, MD, PhD
Dr. Oh discusses updates on JAK inhibitors, a pivotal drug class in the treatment of myelofibrosis.
Read More |
Continuing Education
Meeting Highlights in Myelofibrosis from the ASH Annual Meeting
Andrew Kuykendall, MD; Stephen T. Oh, MD, PhD; and Haris Ali, MD |
Continuing Education
New and Emerging Directions in Myelofibrosis Treatment: Seeking to Improve Quality of Life and Prolong Survival
Srdan Verstovsek, MD, PhD; Rami S. Komrokji, MD; Pankit Vachhani, MD |
Continuing Education
Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO |
Continuing Education
Beyond Ruxolitinib as the Frontline Standard of Care:
Current and Emerging Second-Line Therapies
Prithviraj Bose, MD; and Andrew Kuykendall, MD |
Continuing Education
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
Prithviraj Bose, MD; and John Mascarenhas, MD |
FAQ
Other than cytopenias, what are signs that my patient is intolerant to ruxolitinib or a JAK inhibitor?
Sandra Kurtin, PhD, ANP-C, AOCN, FAPO |
FAQ
What are the updates from ASH regarding new treatments or new data for patients with myelofibrosis?
John O. Mascarenhas, MD |
What are MPNs?
What are Myeloproliferative neoplasms (MPNs)? |
FAQ
Can we predict which patients will respond to a JAK inhibitor?
Andrew Kuykendall, MD and Prithviraj Bose, MD |
FAQ
As a clinician, what should guide my decision on which second-line therapy to choose for my patients?
Prithviraj Bose, MD |
FAQ
What key defining point should community providers be aware of when looking at patients considered to have failed ruxolitinib or have achieved only suboptimal response?
John Mascarenhas, MD
View all FAQs |
